Atossa Therapeutics, Inc. Market Research Report

Background

Company Overview

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative medicines for oncology, with a primary focus on breast cancer. The company's lead product candidate, (Z)-endoxifen, is a potent selective estrogen receptor modulator/degrader (SERM/D) designed to address significant unmet medical needs across the breast cancer treatment continuum.

Mission and Vision

Atossa's mission is to transform breast cancer care through breakthrough science and patient-centric solutions. The company envisions a future where breast cancer is treated more effectively and with fewer side effects, empowering patients at every stage of their journey.

Industry Significance

Breast cancer is the second leading cause of cancer death among American women, with approximately 170,000 women in the U.S. living with metastatic breast cancer. Atossa's focus on developing therapies for metastatic breast cancer addresses a critical area of unmet need in oncology.

Key Strategic Focus

Core Objectives

Atossa aims to advance (Z)-endoxifen through clinical studies, focusing on its potential in metastatic breast cancer, breast cancer prevention, and neoadjuvant treatment settings. The company is committed to improving patient outcomes and creating sustainable value for shareholders.

Areas of Specialization

The company's specialization lies in developing oral formulations of (Z)-endoxifen, designed to be nearly 100 times more potent than other SERMs, with a potentially improved tolerability profile.

Key Technologies Utilized

Atossa employs proprietary oral, enteric-coated formulations of (Z)-endoxifen to enhance bioavailability and stability, overcoming limitations of prior formulations.

Primary Markets Targeted

The primary markets targeted include metastatic breast cancer, breast cancer prevention, and neoadjuvant treatment settings. Additionally, Atossa is exploring applications of (Z)-endoxifen in rare diseases such as Duchenne muscular dystrophy.

Financials and Funding

Funding History

Atossa has raised capital through various funding rounds, including its initial public offering (IPO) in November 2012. As of March 2025, the company reported cash and cash equivalents of $71.1 million, with no debt.

Recent Funding Rounds

Specific details regarding recent funding rounds are not publicly disclosed.

Notable Investors

Investor information is not publicly disclosed.

Utilization of Capital

The capital raised is intended to support the advancement of (Z)-endoxifen through clinical trials, expansion of the company's intellectual property portfolio, and operational capabilities required for late-stage development and potential commercialization.

Pipeline Development

Key Pipeline Candidates

(Z)-Endoxifen: A potent SERM/D being developed for metastatic breast cancer, breast cancer prevention, and neoadjuvant treatment settings.

Stages of Development

(Z)-endoxifen is currently in multiple Phase 2 clinical trials, including studies in women with ductal carcinoma in situ and ER+/HER2- breast cancer.

Target Conditions

The primary target conditions are metastatic breast cancer, breast cancer prevention, and neoadjuvant treatment settings.

Anticipated Milestones

Atossa plans to advance (Z)-endoxifen through additional clinical trials, with a focus on demonstrating its efficacy and safety profile in the targeted indications.

Technological Platform and Innovation

Proprietary Technologies

Atossa's proprietary technology includes the development of oral, enteric-coated formulations of (Z)-endoxifen, designed to enhance bioavailability and stability.

Significant Scientific Methods

The company employs adaptive trial designs and proactive regulatory engagement to advance (Z)-endoxifen across multiple clinical settings.

Leadership Team

Steven C. Quay, M.D., Ph.D.

Position: President and Chief Executive Officer

Professional Background: Dr. Quay is an American author, scientist, and businessman. He received his education from the University of Michigan Medical School and completed his doctorate in 1975. He has previously worked as a faculty member of the Department of Pathology at Stanford University School of Medicine.

Contributions: As CEO, Dr. Quay has led Atossa Therapeutics in its strategic focus on developing (Z)-endoxifen for various breast cancer indications.

Kyle Guse, Esq., CPA

Position: Chief Financial Officer, General Counsel, and Secretary

Professional Background: Mr. Guse serves as the Chief Financial Officer, General Counsel, and Secretary of Atossa Therapeutics.

Contributions: Mr. Guse plays a key role in managing the company's financial operations and legal affairs.

Leadership Changes

As of March 2026, there have been no publicly disclosed significant changes or appointments within Atossa Therapeutics' leadership team.

Competitor Profile

Market Insights and Dynamics

The global breast cancer therapeutics market was valued at approximately $38.5 billion in 2025, with the hormone therapy segment estimated between $15-20 billion. The U.S. breast cancer therapeutics market was valued at $11.9 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 7.9% through 2034.

Competitor Analysis

Atossa faces competition from established pharmaceutical companies with significant market presence, including:

Novartis: Offers Ibrance (palbociclib), a CDK4/6 inhibitor with approximately $5 billion in global sales in 2023.

AstraZeneca/Daiichi Sankyo: Provides Enhertu (trastuzumab deruxtecan), an ADC with nearly $3 billion in sales in 2024.

Merck & Co.: Markets Keytruda (pembrolizumab), a PD-1 inhibitor with oncology sales exceeding $17 billion in 2023.

Strategic Collaborations and Partnerships

In November 2022, Atossa invested $2 million to acquire a 19.99% stake in Dynamic Cell Therapies, Inc., a developer of CAR-T therapies, as part of its strategy to expand into the immuno-oncology space.

Operational Insights

Atossa's focus on developing oral formulations of (Z)-endoxifen positions it to offer a potentially more patient-friendly alternative to existing therapies like tamoxifen. However, the company faces challenges in competing against established products with significant market share and resources.

Strategic Opportunities and Future Directions

Atossa plans to advance (Z)-endoxifen through additional clinical trials, focusing on demonstrating its efficacy and safety profile in metastatic breast cancer, breast cancer prevention, and neoadjuvant treatment settings. The company aims to leverage its proprietary formulation to differentiate itself in the competitive landscape.